CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.47 USD
-0.09 (-3.39%)
Updated Jun 7, 2024 03:55 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 41 - 60 ( 217 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: Nash Trial Begins - First Patient Enrolled
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Looking to 1H22 for Major Catalysts; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated: A Cure in One Patient with Liver Cancer?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
5 Years and Counting Complete Response Observed With Namodenoson
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Piclidenoson and Namodenoson Are on Track for an Eventful 2022; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Clinical Program Advancement Backed by a Growing Number of Distribution Agreements
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated -Piclidenoson Trial Hits the ? Mark
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY-Rated - Reports 2020 - Milestones Ahead
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
2020 a Year of Robust Clinical Proof-of-Concept Demonstration With Piclidenoson and Namodenoson; Reit Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
BUY Rated: Ewopharma Cuts a Deal After Six Months of Diligence
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Strategic Deal Maintains Freedom to Operate in Larger Territories; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V